AMGN (amgen.com) Quarterly EPS earnings growth

Corporate emblem and logo of Amgen Corporation (AMGN)

Can Amgen Inc. (AMGN) maintain its margins amid a fierce battle over patents? Quarterly earnings per share growth provides the answer: the 19.40 level reflects the current value of this metric. The company's own plants in the US and Puerto Rico ensure business stability. The high profitability of complex drugs is offset by massive expenditures on clinical trials for new product lines.

Amgen (AMGN) - Year-over-year net earnings per share change for the last twelve months from 07/04/2022 to 11/15/2026

Metric breakdowns and analytics for Amgen Inc. (AMGN)

- market value and analyst target forecast:
Price Chart Amgen Corporation|AMGN - Price Target Chart
- business market valuation indicators:
Market Capitalization Amgen Corp|AMGN - Business Value
- balance sheet net asset value indicators:
Book Value per Share Amgen|AMGN - Book Valuation of Business|Market Value to Book Value Ratio amgen.com|AMGN - Total Business Assets
- debt and solvency information:
Total Debt to Capital Amgen Inc.|AMGN - Long-Term Indebtedness to Equity|Short-Term Debt to Capital amgen.com|AMGN - Company Aggregate Debts|Debt to Book Capitalization Ratio Amgen Inc.|AMGN - Company Long-Term Liabilities|Company Short-Term Debts Amgen|Quick Ratio amgen.com
- earnings and valuation multiples indicators:
AMGN - Company Net Income|Expected Profit Amgen Inc.|AMGN - Price to Earnings Multiple|Projected Price to Earnings Amgen Inc.|AMGN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Amgen Corp|AMGN - Operating income before deduction of amortization|Earnings per share for the last twelve months Amgen|AMGN - Earnings per share for the last 12 months|Quarterly EPS earnings growth amgen.com|AMGN - Net earnings per share growth this year|Expected earnings per share growth for next year Amgen Inc.
- sales and revenue data:
AMGN - Company Gross Revenue|Projected Sales Volume Amgen Corp|AMGN - P/S Multiple|Price-to-Projected Revenue Ratio Amgen Inc.
Initial company analysis:Amgen Inc.
Flagship merchandise of Amgen Inc

The effectiveness of the M&A strategy of Amgen Inc. (AMGN) determines the overall financial stability of the business. Earnings per share dynamics reflect the growth rate of net income relative to the previous quarter. This metric reveals hidden market imbalances and the actual resilience of the capital. It is critical for investors to evaluate the synergy from the acquisition of biotech startups through the lens of profitability. Analysis based on the quarterly change in EPS allows for the timely detection of a slowdown in operational efficiency.

Main competitors

LLY: Quarterly EPS earnings growth|ABBV (Abbvie) - Year-over-year earnings per share growth for the last twelve months|AZN (astrazeneca.com) - Quarterly EPS earnings growth|novartis.com (NVS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Merck Sharp & Dohme (MRK)|Novo Nordisk - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth PFE (Pfizer Inc)|Net earnings per share growth for the trailing year Sanofi Group|Bristol-Myers Squibb - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year GlaxoSmithKline (GSK)|TAK: Quarterly EPS earnings growth|TEVA: Year-over-year earnings per share growth rate for the last twelve months|Year-over-year net earnings per share growth for the last 12 months RDY|Viatris Corp (VTRS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth ROIV|Year-over-year net earnings per share change for the last twelve months Zai Lab|Quarterly EPS earnings growth BHC (Bausch Health Companies Inc.)|COSM - Year-over-year net earnings per share growth for the last 12 months